Stone House Investment Management’s Viking Therapeutics VKTX Stock Holding History

Stone House Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.2K	Hold	800	–	–	﹤0.01%	275
2026 Q1	$26K	Hold	800	–	–	﹤0.01%	254
2025 Q4	$28.1K	Hold	800	–	–	﹤0.01%	220
2025 Q3	$21K	Hold	800	–	–	﹤0.01%	222
2025 Q2	$21.2K	Buy	800 +500	+167%	+$13.2K	﹤0.01%	210
2025 Q1	$7.25K	Buy	+300	New	+$9.48K	﹤0.01%	279
2024 Q4	–	Sell	-500	Closed	-$31.7K	–	345
2024 Q3	$31.7K	Buy	500 +200	+67%	+$11.7K	0.01%	146
2024 Q2	$15.9K	Hold	300	–	–	﹤0.01%	195
2024 Q1	$24.6K	Buy	300 +50	+20%	+$2.23K	0.01%	181
2023 Q4	$4.65K	Hold	250	–	–	﹤0.01%	219
2023 Q3	$2.77K	Hold	250	–	–	﹤0.01%	240
2023 Q2	$4.05K	Buy	+250	New	+$5.24K	﹤0.01%	217

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Stone House Investment Management's VKTX Position: Q2 2026 in Review

Stone House Investment Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 800 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #275.

Stone House Investment Management first reported a position in VKTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $31.7K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Stone House Investment Management held 800 shares of Viking Therapeutics worth $31.2K as of Q2 2026.
Stone House Investment Management left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #275 holding.
Stone House Investment Management first reported a position in Viking Therapeutics in Q2 2023 and has held it in 12 quarters since.
Stone House Investment Management's Viking Therapeutics position peaked at $31.7K in Q3 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.